newsfilter
← Latest News
GlobeNewswire·

NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022

--NGM707, NGM Bio's most advanced myeloid reprogramming antibody product candidate, will be showcased in the third of a four-part series titled the "Explorer Series"-- SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceutic